NASDAQ:ARVNArvinas Stock Price, Forecast & News

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARVN shares have decreased by 32.1% and is now trading at $29.90.
View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arvinas.

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Arvinas.

Arvinas Inc (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.06. Arvinas had a negative net margin of 182.59% and a negative return on equity of 31.97%.
View Arvinas' earnings history.

11 brokerages have issued 1-year target prices for Arvinas' stock. Their forecasts range from $38.00 to $75.00. On average, they anticipate Arvinas' stock price to reach $57.10 in the next year. This suggests a possible upside of 91.0% from the stock's current price.
View analysts' price targets for Arvinas.

News headlines about ARVN stock have trended somewhat positive on Thursday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arvinas earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Arvinas.

Arvinas saw a increase in short interest in June. As of June 30th, there was short interest totaling 3,300,000 shares, an increase of 13.8% from the June 15th total of 2,900,000 shares. Based on an average daily volume of 608,400 shares, the short-interest ratio is currently 5.4 days. Approximately 12.9% of the company's stock are sold short.
View Arvinas' Current Options Chain.

Some companies that are related to Arvinas include Zai Lab (ZLAB), Myokardia (MYOK), Legend Biotech (LEGN), HUTCHISON CHINA/S (HCM), HYPERA S A/S (HYPMY), GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), Allakos (ALLK), Opko Health (OPK), Nektar Therapeutics (NKTR) and FibroGen (FGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), ImmunoGen (IMGN), Krystal Biotech (KRYS), Protalix Biotherapeutics (PLX), Senseonics (SENS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Vaxart (VXRT).

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.93%), Rossmore Private Capital (0.26%), First Trust Advisors LP (0.11%), Swiss National Bank (0.11%), Principal Financial Group Inc. (0.06%) and UBS Group AG (0.06%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, John G Houston, Liam Ratcliffe, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas.

ARVN stock was sold by a variety of institutional investors in the last quarter, including Rossmore Private Capital, and Russell Investments Group Ltd.. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, and Sean A Cassidy.
View insider buying and selling activity for Arvinas.

ARVN stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Principal Financial Group Inc., First Trust Advisors LP, UBS Group AG, Quantitative Systematic Strategies LLC, Swiss National Bank, Strs Ohio, and ProShare Advisors LLC. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, and Timothy M Shannon.
View insider buying and selling activity for Arvinas.

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARVN stock can currently be purchased for approximately $29.90.

Arvinas has a market capitalization of $1.17 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]